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Résumé en
anglais
Blood flow reduction induces inward remodeling of resistance arteries (RAs). This
remodeling occurs in ischemic diseases, diabetes and hypertension. Nonetheless, the
effect of flow reduction per se, independent of the effect of pressure or metabolic
influences, is not well understood in RA. As angiotensin II is involved in the response
to flow in RA, we hypothesized that angiotensin II may also be involved in the
remodeling induced by a chronic flow reduction. We analyzed the effect of
angiotensin I-converting enzyme inhibition (perindopril) and angiotensin II type 1
receptor blockade (candesartan) on inward remodeling induced by blood flow
reduction in vivo in rat mesenteric RAs (low flow (LF) arteries). After 1 week,
diameter reduction in LF arteries was associated with reduced endothelium-
dependent relaxation and lower levels of eNOS expression. Superoxide production
and extracellular signal-regulated kinases 1/2 (ERK1/2 phosphorylation were higher
in LF than in normal flow arteries. Nevertheless, the absence of eNOS or superoxide
level reduction (tempol or apocynin) did not prevent LF remodeling. Perindopril and
candesartan prevented inward remodeling in LF arteries. Contractility to angiotensin
II was reduced in LF vessels by perindopril, candesartan and the ERK1/2 blocker
PD98059. ERK1/2 activation (ratio phospho-ERK/ERK) was higher in LF arteries, and
this activation was prevented by perindopril and candesartan. ERK1/2 inhibition in
vivo (U0126) prevented LF-induced diameter reduction. Thus, inward remodeling
because of blood flow reduction in mesenteric RA depends on unopposed angiotensin
II-induced contraction and ERK1/2 activation, independent of superoxide production.
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